Transcription factors in liver fibrosis: Mechanistic insights and nanotechnology-driven therapeutic strategies (Review)
4 affiliations
- 1Department of Hepatobiliary Surgery, Taizhou Municipal Hospital (Taizhou University Affiliated Municipal Hospital), School of Medicine, Taizhou University, Taizhou, Zhejiang 318001, P.R. China
- 2Department of Pathophysiology, School of Basic Medicine, Shenyang Medical College, Shenyang, Liaoning 110000, P.R. China
- 3School of Art and Design, Taizhou University, Taizhou, Zhejiang 318001, P.R. China
- 4Department of Basic Medicine and Medical Laboratory Science, School of Medicine, Taizhou University, Taizhou, Zhejiang 318001, P.R. China
Abstract
Liver fibrosis, a common pathological outcome of chronic liver diseases, is a dynamic process characterized by molecular and cell interactions. Transcription factors (TFs) are key in modulating gene expression programs that govern hepatocyte fate, metabolic homeostasis, inflammation and extracellular matrix remodeling. In hepatocytes, TFs such as hepatocyte nuclear factor 4α and FOXA2 serve a key role in maintaining metabolic balance, with their dysfunction leading to lipid accumulation, oxidative stress and profibrotic signaling. In non-parenchymal cells, including hepatic stellate, Kupffer and liver sinusoidal and biliary epithelial cells, TFs such as YAP/TAZ, NF-κB, STAT3 and GATA-binding factor 4 regulate activation, proliferation and intercellular communication, thereby influencing fibrosis progression or resolution. Advances in single-cell omics, spatial transcriptomics and epigenomics are elucidating the dynamic, cell type-specific TF networks involved in fibrosis and identifying therapeutic targets. Nanotechnology presents strategies for precise modulation of TFs and selective targeting of hepatic cell populations, facilitated by nanocarriers that enable the delivery of nucleic acids, pathway inhibitors and epigenetic modulators. Preclinical studies indicate promising antifibrotic effects of nanodelivery systems, however, challenges related to biocompatibility, targeting efficiency and clinical translation persist. This review aimed to summarize TF-mediated regulation in liver fibrosis and nanotechnology-based therapeutic approaches as well as future directions for precision antifibrotic therapy.
Related
- Lactylation in liver fibrosis: from molecular mechanisms to targeted therapeutic strategies
- Differential functions of ROCK1 and ROCK2 in liver fibrosis and advances in targeted therapeutic strategies
- AI-based strategies for diagnosis and therapeutic discovery in pulmonary fibrosis.
- Nanotechnology-enabled strategies to improve stem cell therapy for erectile dysfunction.
- Transcription Regulatory Sequences in Coronaviruses: Mechanistic Foundations for Antivirals and Vaccines.
BibTeX
@article{zhou2026transcription,
title = {{Transcription factors in liver fibrosis: Mechanistic insights and nanotechnology-driven therapeutic strategies (Review)}},
author = {Xianfei Zhou and Chongjun Yang and Zhiyong Weng and Lihua Li},
journal = {International Journal of Molecular Medicine},
year = {2026},
month = oct,
doi = {10.3892/ijmm.2026.6020},
url = {https://doi.org/10.3892/ijmm.2026.6020},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Transcription factors in liver fibrosis: Mechanistic insights and nanotechnology-driven therapeutic strategies (Review)
AU - Xianfei Zhou
AU - Chongjun Yang
AU - Zhiyong Weng
AU - Lihua Li
PY - 2026
DA - 2026/10/21
JO - International Journal of Molecular Medicine
DO - 10.3892/ijmm.2026.6020
UR - https://doi.org/10.3892/ijmm.2026.6020
AB - Liver fibrosis, a common pathological outcome of chronic liver diseases, is a dynamic process characterized by molecular and cell interactions. Transcription factors (TFs) are key in modulating gene expression programs that govern hepatocyte fate, metabolic homeostasis, inflammation and extracellular matrix remodeling. In hepatocytes, TFs such as hepatocyte nuclear factor 4α and FOXA2 serve a key role in maintaining metabolic balance, with their dysfunction leading to lipid accumulation, oxidative stress and profibrotic signaling. In non-parenchymal cells, including hepatic stellate, Kupffer and liver sinusoidal and biliary epithelial cells, TFs such as YAP/TAZ, NF-κB, STAT3 and GATA-binding factor 4 regulate activation, proliferation and intercellular communication, thereby influencing fibrosis progression or resolution. Advances in single-cell omics, spatial transcriptomics and epigenomics are elucidating the dynamic, cell type-specific TF networks involved in fibrosis and identifying therapeutic targets. Nanotechnology presents strategies for precise modulation of TFs and selective targeting of hepatic cell populations, facilitated by nanocarriers that enable the delivery of nucleic acids, pathway inhibitors and epigenetic modulators. Preclinical studies indicate promising antifibrotic effects of nanodelivery systems, however, challenges related to biocompatibility, targeting efficiency and clinical translation persist. This review aimed to summarize TF-mediated regulation in liver fibrosis and nanotechnology-based therapeutic approaches as well as future directions for precision antifibrotic therapy.
SN - 1107-3756
SN - 1791-244X
ER -